Liver Transplantation News and Research

RSS

A study analyzes the most important factors leading to death or liver transplant in drug-induced liver disease

Drug-induced liver disease (DILD), a potential complication seen with some medications, is usually not life-threatening, but may occasionally be more severe with a high mortality, requiring a liver transplant in selected cases.

18 Jul 2005

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Leading medical experts from throughout the UK will be gathering in Edinburgh today and tomorrow (21-22 April 2004) to arrive at a consensus on how best to treat and manage the 'silent epidemic' of hepatitis C - a virus which is estimated to be carried by over 400,000 people in the UK and which continues to spread globally, as the majority of carriers do not realise they have been infected.

21 Jun 2005

Tobacco use persists after liver transplant for alcoholic liver disease

Alcohol and tobacco often go hand-in-hand. Studies have shown that approximately 90 percent of problem drinkers also smoke or chew tobacco. But tobacco use is not adequately addressed when patients undergo liver transplantation due to alcoholic liver disease, say authors of a new report.

26 May 2005

Survival rates higher for children receiving living donor liver transplant

Children who undergo liver transplantation have better survival rates with living donor liver transplant graft than with deceased donor organ transplant, although factors other than the type of graft also are important, according to a study in the May issue of Archives of Surgery.

16 May 2005

Monitoring program has successfully identified a large number of previously unknown, serious and often-fatal drug reactions

A monitoring program developed by a Northwestern University researcher has successfully identified a large number of previously unknown, serious and often-fatal drug reactions associated with 15 commonly used drugs, including Plavix®, thalidomide and drug-coated cardiac stents.

3 May 2005

High levels of immunosuppressant may lead to tumor recurrence

A new study on the incidence of liver cancer after transplant found that high levels of the immunosuppressant cyclosporine favored tumor recurrence and identified blood levels of the drug that should not be exceeded. Lower levels of cyclosporine levels did not affect rejection rates.

22 Apr 2005

New trial for treatment of liver disease

The Nonalcoholic Steatohepatitis (NASH) Clinical Research Network is launching its first two clinical trials for the study of NASH, a liver disease that resembles alcoholic liver disease but occurs in patients who drink little or no alcohol.

3 Apr 2005

Three risk factors have the greatest impact on patient and graft survival rates for liver transplantation

Three risk factors: donor age; the length of time an organ is cooled between procurement and transplantation; and how urgently the recipient needs the transplant; have the greatest impact on patient and graft survival rates for liver transplantation, according to an article in the March issue of Archives of Surgery.

22 Mar 2005

Donor age has no affect on long-term liver transplant survival

A new study on the effect of donor age on survival and recurrence of hepatitis C after liver transplantation found that it influenced short-term survival, but had no long-term effect.

22 Mar 2005

Alcohol relapse adversely affects liver transplant survival

A new study on how alcohol relapse affects survival rates after liver transplants found that it adversely affected survival rates only after 10 years. The decrease in survival rates may, however, be due to other alcohol-related diseases.

22 Mar 2005

New study to evaluate Pegasys and Copegus to treat hepatitis C in liver transplant patients

Roche has initiated a new study to evaluate treatment strategies to reduce post-transplant recurrence of hepatitis C infection with the most prescribed hepatitis C treatment combination in the U.S., Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP).

21 Mar 2005

Pfizer acquires Idun Pharmaceuticals

Pfizer today announced that it has entered into an agreement to acquire Idun Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases.

24 Feb 2005

Green tea protects livers

A new study investigating the effects of the major flavonoid component of green tea on hepatic steatosis (fatty liver) found that it significantly protected livers that suffered ischemia/reperfusion (I/R) injury in mice. I/R injury, which is caused by decreased blood flow, can lead to complications after liver transplantation.

20 Feb 2005

Biochemical marker aids prognosis in liver transplant patients

A new study on whether the model used to identify patients most in need of a liver transplant can be improved upon found that measuring serum sodium in potential transplant patients helps to better predict those with a poor prognosis.

20 Feb 2005

Severity of liver disease not a reliable indicator of quality of life

A new study on the determination of how livers are allocated for transplants examined the relationship between liver disease severity and quality of life, and found that the commonly used model for liver allocation is not a reliable indicator of general quality of life.

24 Jan 2005